Editor’s note: A livestream of this event will be embedded below at 1 p.m. ET.
Several biosimilar versions of Humira, which for years has been the world’s best-selling medicine, entered the U.S. market over the past year. What has that meant for insurance coverage and the way drugmakers are marketing these medicines? Join leading experts to discuss the impact on the industry and patients.
Imagine a country with a billion people, where every individual has different interests and different goals. You will never know their interests and goals until
Good morning, everyone, and welcome to another working week. We hope the weekend respite was sufficiently relaxing and invigorating, because that oh-so-familiar routine of online
Post-hoc analyses are generally a major no-no for the FDA, but agency reviewers signaled their openness to considering them in the case of Ipsen’s potential